We cordially invite you to attend our 4th Annual CEO Summit!

Igniting a Spark & Blazing the Way to 1 Million IVF Cycles

November 12, 2020 | Virtual 6:00pm - 7:00pm CST | $25 per person

A can’t miss event, join us for the 4th Annual CEO Summit Dinner: Igniting a Spark & Blazing the Way to 1 Million IVF Cycles! Keynote speakers David Sable, MD and Afton Vechery will share how they sparked their own hot path to success and how we can all blaze the way to 1 million IVF cycles! Hear first hand strategies and tactics that you can take back to improve your organization's road to success and join us on the path to 1 million. Are you up for the challenge?!?! 

Register Today!

To register, make sure you are logged into your MRSi profile account, and register for your ticket here! If you don't have an MRSi profile account, click here to create one for free. You must have a profile account to register for events.

Practice Special Pricing: 

We know these are trying times with both staff time and finances, so we are offering: Practice Special Rates: $99 4-9 participants or $225, 10-19 participants. Those who attend the sessions can receive CE/CME. The recordings will be available after the meeting for those who couldn’t make all the sessions or want to watch again. Email Coordinators@mrsmeeting.org to get your practice registered for the meeting!

Graciously Sponsored by:  


David Sable, MD directs healthcare and life science investing for the Special Situations Funds and is portfolio manager for the Special Situations Life Sciences Fund and Life Sciences Innovation Venture Capital funds. After graduating from the Wharton School and the University of Pennsylvania School of Medicine, he trained in obstetrics and gynecology at New York Hospital - Cornell Medical Center, and in reproductive endocrinology at the Brigham and Women's Hospital. He co-founded and served as director of the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey, was founder of Assisted Reproductive Medical Technologies, which was acquired by Saint Barnabas in 1999, and co-founder of Reprogenetics, acquired by Cooper Surgical in 2015. After leaving clinical medicine, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations Funds. 

Dr. Sable is an adjunct in the department of biology at Columbia University, and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences. He serves on the board of directors for Hamilton Thorne Ltd, MedAnswers Inc, Ohana Biosciences Inc., and Celmatix Inc, and is a clincal advisory board member and board observer for TMRW Life Sciences. He previously served as a board member for Genenews Inc, for the nonprofit advocacy organization RESOLVE, on the medical advisory board for Progyny Inc and on the scientific advisory board of Ovascience Inc. In addition to his academic publications, he has written for the Newark Star-Ledger, Yoga Journal, Xconomy, Genetic Engineering and Biotechnology News, Wharton Magazine, and is a regular contributor to Forbes, covering the reproductive medicine industry.

Afton Vechery is the CEO and Co-founder of Modern Fertility, the women's health company making personalized fertility information more accessible to women everywhere. Modern Fertility offers the first comprehensive hormone test you can take at home to check in on fertility hormones, providing women with a proactive and informed way to learn about their reproductive health. Under Afton's leadership, Modern Fertility has built a new approach to fertility education—one that’s grounded in clinical rigor, the latest research, community support, and neutral, personalized information. 

To further its goal, Modern Fertility has published multiple clinical studies that advance fertility science and help women better understand fertility. Modern Fertility’s first study demonstrated that its home test and a traditional venous blood draw are concordant. This study was published in the Green Journal, reviewed in the New England Journal of Medicine, and selected for a prize paper presentation at the American Society for Reproductive Medicine in 2018. Additional Modern Fertility research dives into the cultural elements of fertility, including studies on common fertility knowledge gaps, the desire for new information and support channels, as well as LGBTQ+ fertility and family planning. All research has been carried out in close collaboration with Modern Fertility’s Medical Advisory Board. 

Modern Fertility is the fourth health company that Afton has had a hand in launching. Before Modern Fertility, Afton worked in healthcare private equity, leading diligence into IVF clinics and laboratories, before leading strategic operations at various healthtech startups. Afton was most recently a product leader at 23andMe, overseeing the consumer tools division. Afton was named to the Forbes 30 Under 30 list as well as Inc Magazine's 30 Under 30 list, and Modern Fertility was named Fast Company's most innovative healthcare company in the world in 2019 and one of CNBC's most promising startups to watch in 2019.